Search results
Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
BioPharma Dive via Yahoo Finance· 3 days agoLeqembi’s arrival was seen as a development that would usher in widespread use, but Eisai and Biogen...
Lilly's Alzheimer's drug faces delayed reckoning
Axios· 4 days agodrug shown to delay Alzheimer's disease will come into focus Monday, when Food and Drug Administration advisers review an application from Eli Lilly...
Calico Life Sciences Announces that Fosigotifator (ABBV-CLS-7262) for Vanishing White Matter Disease...
Tehachapi News· 7 days agoFDA's Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) initiated the START Pilot Program to help further accelerate the ...
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Zacks via Yahoo Finance· 1 day agoSeveral companies have failed to develop safe and effective treatment options to treat this deadly ...
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
Zacks via Yahoo Finance· 3 days agoBiogen/Eisai’s controversial medicine, Aduhelm, was approved by the FDA in 2021. However, in January...
Eli Lilly stock hits all-time high: What’s been driving the pharma giant’s share price higher?
Bankrate via Yahoo Finance· 2 days agoHowever, investors should remain cautious. The full impact of donanemab on the Alzheimer’s treatment...
Alzheon secures $100m to advance Alzheimer’s disease treatment
Pharmaceutical Technology via Yahoo Finance· 1 day agoThe development comes after the company raised $50m in a Series D round in 2022. The...patients. The...
Experimental GLP-1 med may be breakthrough against fatty liver disease
Medical Xpress· 4 days agoThe drug under development, survodutide, helped up to 83% of patients gain real improvements in...
Skye Bioscience to stop eye disease drug development after failing mid-stage study
Reuters via Yahoo News· 4 days agoIn the 56-subject study, the eye drop, SBI-100, failed to significantly lower eye pressure in patients with primary open-angle glaucoma when compared with the placebo, the company said. In this ...
Lilly Alzheimer’s drug gets unanimous backing of FDA panel
BioPharma Dive via Yahoo Finance· 4 days agoLilly executives said that, later in the trial, they were able to better identify asymptomatic cases...